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Background: Molds and other pathogens induce elevated levels of several cytokines,
including interleukin (IL)-6 and IL-8. The objective of this study was to investigate
the prognostic value of IL-6 and IL-8 as well as fungal biomarkers in blood and
bronchoalveolar lavage fluid (BAL) for overall survival in patients with underlying
hematological malignancies and suspected mold infection.
Methods: This cohort study included 106 prospectively enrolled adult cases undergoing
bronchoscopy. Blood samples were collected within 24 h of BAL sampling and, in
a subset of 62 patients, serial blood samples were collected up until 4 days after
bronchoscopy. IL-6, IL-8, and other cytokines as well as galactomannan (GM) and
β-D-glucan (BDG) were assayed in blood and BAL fluid and associations with overall
mortality were assessed at the end of the study using receiver operating characteristic
(ROC) curve analysis.
Results: Both blood IL-8 (AUC 0.731) and blood IL-6 (AUC 0.699) as well
as BAL IL-6 (AUC 0.763) and BAL IL-8 (AUC 0.700) levels at the time of
bronchoscopy were predictors of 30-day all-cause mortality. Increasing blood
IL-6 levels between bronchoscopy and day four after bronchoscopy were
significantly associated with higher 90-day mortality, with similar findings for
increasing IL-8 levels. In ROC analysis the difference of blood IL-8 levels
between 4 days after bronchoscopy and the day of bronchoscopy had an
AUC of 0.829 (95%CI 0.71–0.95; p < 0.001) for predicting 90-day mortality.
Rawlings et al. Blood Interleukins and Overall Mortality
Conclusions: Elevated levels of IL-6 and IL-8 in blood or BAL fluid at the time of
bronchoscopy, and rising levels in blood 4 days following bronchoscopy were predictive
of mortality in these patients with underlying hematological malignancy who underwent
bronchoscopy for suspected mold infection.
Keywords: hematologic malignancy, invasive mold infection, interleukin-6, interleukin-8, prognosis
INTRODUCTION
Patients with hematologic malignancies are
immunocompromised with increased rates of hospital
admissions and, in particular, admissions to the intensive
care unit (ICU) (1). Factors that increase the risk of admission
to the ICU include pneumonia caused by invasive mold
infections (IMI) or other pathogens (2). IMI, including invasive
aspergillosis (IA), are associated with high morbidity and
mortality among patients with underlying hematological
malignancies (3–7). Prognosticating survival in patients at risk
for IMI remains difficult (8), although prompt identification of
those most at risk for severe complications and death and early
initiation of antifungal or other anti-infective therapy could lead
to better outcomes (9).
Aspergillus spp. have been shown to induce T-helper cell
subsets resulting in elevated levels of several cytokines (10, 11)
and recent studies have indicated—after adjusting for multiple
covariates also associated with higher cytokine levels—that
particularly Interleukin (IL)-8 and IL-6 may show promise
as diagnostic markers (12, 13). Our own work suggests that
elevated levels of IL-8 in patients presenting with suspected
pulmonary infection have excellent specificity (>90%) for
detecting IMI (14), however whether these cytokines may
also predict overall mortality and whether serial measurement
of this cytokines may increase their prognostic potential
remains unknown.
The objective of this analysis was to determine the
potential of variations in IL-6 and IL-8, as well as established
fungal biomarkers, to predict overall mortality in patients
with underlying hematological malignancies and suspicion
of pulmonary mold infection in a setting that uses mold-
active prophylaxis.
MATERIALS AND METHODS
This prospective cohort study comprised paired routine serum
and BAL samples obtained on the same day from cases
with underlying hematological malignancies who underwent
routine bronchoscopy due to suspicion of pulmonary mold
infections. The decision was based on suspicious or non-
specific radiological findings in chest computed tomography,
with or without clinical laboratory findings including fungal
biomarker levels. Investigators had no influence on clinical
interventions (e.g., bronchoscopy) and treatment of the enrolled
patients. The diagnostic potential of several biomarkers and
cytokinesmeasured in same day BAL and blood samples obtained
as part of this cohort study for diagnosing IMI has been
previously published (13, 14). However, the present analysis
focuses on the overall prognostic potential of several cytokines
and biomarkers in clinical outcomes of IMI. Approximately
halfway through the study, the protocol was modified to
include permission to use routinely-collected surplus plasma
samples stored in the hospital laboratory for 4 days following
collection. These longitudinal samples have not previously
been published.
IA and IMI were graded in accordance with the revised criteria
by the European Organization for Research and Treatment of
Cancer Invasive Fungal Infections Cooperative Group (EORTC)
and the Mycoses Study Group of the National Institute of Allergy
and Infectious Disease (MSG) (15).
Study Cohort
Participants undergoing bronchoscopy were prospectively
enrolled at the Medical University of Graz, Graz, Austria,
between April 2014 and July 2017. Key inclusion criteria were
(i) adult patients with (ii) underlying hematological malignancy
who were (iii) at risk for IMI according to the attending clinicians
discretion (e.g., febrile neutropenia, induction chemotherapy for
acute myeloid leukemia, allogeneic stem cell transplantation),
had (iv) a BAL sample obtained due to clinical suspicion of
pulmonary infection, and (v) an order of fungal biomarkers from
BAL [i.e., galactomannan (GM) and in a subset also panfungal
or Mucorales specific polymerase chain reaction]. All patients
who met inclusion criteria between April 2014 and July 2017
and signed an informed consent were included in the cohort.
After informed consent was obtained, serum and whole blood
samples were collected within 24 h of bronchoscopy. In the last
62 patients enrolled in the study, serial daily plasma samples
were also obtained from blood samples drawn as part of routine
clinical care from 4 days before bronchoscopy until 4 days after
bronchoscopy. Because Investigators had no influence on blood
sample drawn besides the same-day samples, sample size varied
between 2 and 9 plasma samples per case. These were stored
at 4◦C for up to 4 days before processing for storage at −70◦C
and analysis.
Biomarker Testing
Conventional culture as well as BAL and serum GM
concentrations (Platelia enzyme immunoassay; Bio-Rad
Laboratories, Vienna, Austria) were prospectively determined
in clinical routine at the Medical University of Graz. Given that
the vast majority of patients received mold-active antifungals
at the time of bronchoscopy, cut-offs of 0.5 GM optical density
index (ODI) where used for serum and BAL, following previous
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evidence that the 0.5 ODI cutoff is preferable in patients on
mold-active antifungals (16).
β-D-glucan (BDG) testing was performed in part
prospectively and in part retrospectively at the Medical
University of Graz, using the commercially available Fungitell R©
assay (Cape Cod Diagnostics, Falmouth, MA, USA) with an
adopted protocol suitable for use on a routine BCS XP R©
coagulation analyzer, as described previously (17). BDG testing
was only performed in serum samples, as BAL BDG testing
yields very low specificity due to non-pathogenic Candida
colonization in the lungs and high BDG values (18–20). For
serum BDG we used the recommended cut-off of ≥ 80 pg/mL to
define positivity.
All blood (i.e., serum and plasma) and BAL isolates used
in this study were frozen to −70◦C after processing and
stored for batched analysis. IL-6 and IL-8 concentrations were
determined in serum, plasma, and BAL samples at the Center
for Medical Research of the Medical University of Graz,
Austria, between 09/2016 and 10/2017 with a personalized
ProcartaPlex R© immunoassay (eBioscience, Vienna, Austria) as
previously described (13).
Investigators measuring biomarkers and cytokine levels
were blinded toward clinical and demographic information of
the patients.
Assessing Mortality
All patients enrolled in the study were followed clinically on
initial admission and their medical records were reviewed after
discharge. Autopsies were not routinely performed or requested
as part of the study and therefore the absolute rate of autopsies
on patients in the study was very low—likely reflecting the low
cultural predilection for autopsy in the study country.
Our study was conducted in accordance with the Declaration
of Helsinki, 2013, Good Clinical Practice. The study protocol was
approved by the local ethics committee, Medical University
Graz, Austria (EC-numbers 25-221 and 23-343), and
registered at ClinicalTrials.gov (Identifier: NCT02058316
and NCT01576653). Informed consent was obtained from all
study participants. Statistical analysis was performed using
SPSS, version 25 (SPSS Inc., Chicago, IL, USA). For continuous
data, including cytokine levels, receiver operating characteristic
(ROC) curves analyses were performed and area under the curve
(AUC) values are presented including 95% confidence intervals
(95% CI) for the 30-, 90-, and 180-day overall mortality outcomes
(p-values were not corrected for multiple comparisons). Optimal
cut-offs for cytokines discriminating in patients who died
within 30 days vs. those who survived were calculated using the
Youden’s index. Two-sided p-value < 0.05 was taken as cut-off
for statistical significance.
RESULTS
Study Cohort
In total, 122 participants undergoing bronchoscopy were
prospectively enrolled between April 2014 and July 2017. A
total of 16 cases had to be excluded due to the following
reasons: (i) same day blood samples (i.e., collected within 24-
h) were not available (n = 13); (ii) BAL volume after routine
testing was insufficient for further diagnostic work up within
the study protocol (n = 2); (iii) hematological malignancy was
suspected but not confirmed because of mortality within days
of admission (n = 1). After exclusion of these 16 cases, 106
patients remained in the final analysis. Patients’ characteristics
are displayed in Table 1. Mortality was 16% (17/106) at 30 days,
27.4% (29/106) at 90 days, and 42.5% (45/106) at 180 days
after study enrollment and bronchoscopy. In those with mold
infections, 30-day mortality was 36% for probable/proven IA,
16% for possible IA and 13% for those without evidence for IA
(for all probable/possible/no IMI 33, 12, and 13%, respectively).
Overall patients who died within 30 days weremore frequently
neutropenic at the time of bronchoscopy, had more frequently
received T-cell suppressants, had more frequently probable or
proven IMI and had received more frequently mold active
prophylaxis or treatment at the time of bronchoscopy (Table 1).
Of the 17 cases who died within 30 days of bronchoscopy (median
14 days after bronchoscopy, range 1–30 days), autopsy was
performed in four cases, revealing progression of acute myeloid
leukemia as cause of death in two cases, while cause of death
was infectious (organized viral pneumonia, multi organ failure)
in the other two cases. Of the other 13 cases who did not
undergo autopsy, five had probable IMI, two possible IMI, two
viral pneumonias, and each one bacterial pneumonia or systemic
bacterial infection. Neutropenia and receipt of mold-active
antifungals were also more frequent in those who died within 90
days, in fact every single patient who died within 90 days had
received a mold-active antifungal at the time of bronchoscopy
while this was 74% of patients who survived to day 90 (p= 0.002).
Prognostic Potential of Blood and BAL
Cytokines at the Time of Bronchoscopy
In ROC curve analysis, serum IL-8 was a significant predictor of
30-day overall mortality, followed by serum IL-6, while serum
GM and serum BDG were not significant predictors (Table 2).
In BAL IL-6 and IL-8 were significant predictors of overall 30-
day mortality, while GM was not (Table 2). Both serum IL-8 and
serum IL-6 as well as BAL IL-6 were also significant predictors
of 90- and 180-day cumulative overall mortality, although AUCs
were lower when compared to 30-day mortality, and significance
driven mostly by the predictive potential for 30-day mortality
(Table 2). When focusing only on participants who died within
30- and 90-days, or between 90- and 180-days, AUCs were
highest for serum IL-8 (AUC 0.578 and 0.592, respectively),
followed by serum IL-6 (AUC 0.564 for both; all p > 0.2).
Boxplots of serum and BAL IL-8 and IL-6 levels in those who died
and those who survived are displayed in Figure 1. For prediction
of 30-day mortality, optimal cut-offs were serum IL-8 > 13.93
pg/mL (82.4% sensitivity, 61.8% specificity), serum IL-6 > 165
pg/mL (52.9% sensitivity, 87.6% specificity), BAL IL-8 > 1,111
pg/mL (64.7% sensitivity, 69.7% specificity), and BAL IL-6 >
43.95 pg/mL (100% sensitivity, 46.1% specificity).
Sub-analyses for 30-day mortality found that (i) among
those with possible, probable or proven IMI serum IL-8 (AUC
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TABLE 1 | Demographic data, underlying diseases, and infections in cases who died within 30 and 90 days after bronchoscopy vs. those who survived.
Demographic data, underlying
diseases and other
characteristics at the time of
sampling (n = 106)
Mortality at day 30
(n = 17)
Survival at day 30
(n = 89)
p-value* Mortality at day 90
(n = 29)
Survival at day 90
(n = 77)
p-value*
Sex Female 6 (35%) 47 (53%) >0.2 10 (34%) 43 (56%) 0.050
Male 11 (65%) 42 (47%) 19 (66%) 34 (44%)
Age [years] Median (range) 55 (33–66) 59 (26–85) 0.13 56 (27–78) 58 (26–85) >0.2
Underlying
diseases
AML/MDS 8 (47%) 43 (48%) >0.2 18 (62%) 33 (43%) >0.2
NHL 2 (12%) 22 (25%) 4 (14%) 20 (26%)
MM 2 (12%) 7 (8%) 2 (7%) 7 (9%)
ALL 2 (12%) 9 (10%) 2 (7%) 9 (12%)
Others# 3 (18%) 8 (9%) 3 (10%) 8 (10%)
Other conditions Allogeneic stem cell
transplantation
5 (29%) 23 (26%) >0.2 8 (28%) 20 (26%) >0.2
Autologous stem cell
transplantation
1 (6%) 9 (10%) >0.2 1 (3%) 9 (12%) >0.2
Graft vs. host disease 3 (18%) 13 (15%) >0.2 5 (17%) 11 (14%) >0.2
Neutropenia (<500 µL) on day of
BAL
12 (71%) 34 (38%) 0.017 18 (62%) 28 (36%) 0.017
T-Cell Suppressants within 3
months of BAL
5 (29%) 9 (10%) 0.047 7 (24%) 7 (9%) 0.055
Systemic corticosteroid treatment
within 14 days of sampling
5 (29%) 25 (28%) >0.2 8 (28%) 22 (29%) >0.2
Invasive fungal
infections
Probable/proven IMI 6 (35%) 12 (13%) 0.039 6 (21%) 12 (16%) >0.2
Possible IMI 3 (18%) 22 (25%) >0.2 9 (31%) 16 (21%) >0.2
Probable/proven invasive
aspergillosis
4 (24%) 7 (8%) 0.07 4 (14%) 7 (9%) >0.2
Antimould prophylaxis$/treatment 17 (100%) 69 (78%) 0.030 29 (100%) 57 (74%) 0.002
Other infections Positive diagnostic test for
relevant bacterial pathogens,
pneumocystis or toxoplasma in
BAL
3 (18%) 18 (20%) >0.2 5 (17%) 16 (21%) >0.2
Positive diagnostic test for
bacterial infections in other
samples (blood
culture/biopsies/urine) within 14
days of sampling
5 (29%) 19 (21%) >0.2 9 (31%) 15 (19%) >0.2
Positive diagnostic test for viral
infections within 14 days of
sampling
6 (35%) 32 (36%) >0.2 10 (34%) 28 (36%) >0.2
*Bold indicates p-values that met statistical significance.
#Included 5 chronic lymphoid leukemia (CLL); 3 primary myelofibrosis; 2 Hodgkin’s lymphoma, and 1 anaplastic anemia.
$Breakdown of antifungal prophylaxis: 19 received voriconazole, 18 received posaconazole prophyaxis at the time of sampling.
ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; BAL, bronchoalveolar lavage fluid; GvHD, Graft vs. host disease; IA, invasive aspergillosis; IMI, invasive mold
infection; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-hodgkin lymphoma; SCT, stem cell transplantation.
0.650), BAL IL8 (AUC 0.693), and BAL IL6 (AUC 0.631) had
prognostic potential, while serum-IL-6 did not; (ii) among those
with bacterial infections, serum IL-8 (AUC 0.685), BAL IL-
8 (AUC 0.756), and BAL IL-6 (AUC 0.685) had prognostic
potential, while serum IL-6 did not; (iii) among those with
viral infections, only BAL levels of IL-8 (AUC 0.734) and IL-
6 (AUC 0.677) had prognostic potential, while serum levels
did not; (iv) among those with neutropenia at the time of
bronchoscopy, serum levels of IL-6 (AUC 0.691) and IL-8 (AUC
0.642) had some prognostic potential while BAL levels had not;
in contrast, BAL IL-8 (AUC 0.920) and BAL IL-6 (AUC 0.862)
had very strong prognostic potential among non-neutropenic
patients; (v) among those on corticosteroids, BAL IL-6 (AUC
0.831) and BAL IL-8 (AUC 0.728) levels had stronger prognostic
potential than serum levels; and (vi) among female patients
serum IL-8 (AUC 0.862), serum IL-6 (AUC 0.771), BAL IL-
8 (AUC 0.812), and BAL IL-6 (AUC 0.801) had all strong
prognostic potential.
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Kinetics of Blood IL-6 and IL-8 Before and
After Bronchoscopy
In a subset of 62 participants, serial blood samples were obtained
from 4 days preceding to 4 days following bronchoscopy (this
particular subset had 30-day mortality of 14%, 90-day mortality
of 28%, and 180-day mortality of 50%). Kinetics of serum IL-
8 and IL-6 levels stratified by categories of overall mortality are
displayed in Figures 2, 3 (23 samples tested for Day −4, 42
samples for Day −3, 46 samples for Day −2; 53 samples for Day
−1; 62 samples for Day 0; 48 samples for Day+1; 52 samples for
Day+2; 46 samples for Day+3; 49 samples for Day+4).
Between the day of bronchoscopy and 4 days following
bronchoscopy (samples available from 49 participants on both
time points), blood IL-6 levels increased in 14/49 (29%)
participants, while blood IL-8 levels increased in 19/49 (39%) of
participants. Increasing IL-6 levels at day four were significantly
associated with higher 90-day mortality rates [7/13 (54%) died
vs. 7/36 (19%) with stable or decreasing levels; p = 0.031],
with similar findings for increasing IL-8 levels 4 days following
bronchoscopy [9/18 (50%) died vs. 5/31 (16%); p = 0.020].
In ROC analysis, the difference of IL-8 levels between 4 days
following bronchoscopy and the day of bronchoscopy had an
AUC of 0.829 (95%CI 0.71–0.95; p< 0.001) for predicting 90-day
mortality (AUC for IL-6 0.686; 95%CI 0.499–0.872; p = 0.044).
AUC for IL-8 difference to predict 30-day mortality was 0.771
(95%CI 0.578–0.963; p = 0.023) and for 180-day mortality 0.680
(95%CI 0.529–0.831; p = 0.031); while differences in IL-6 levels
were not significant predictors for 30- and 180-day mortality.
DISCUSSION
We evaluated prognostic potential of IL-6, IL-8, and several
fungal biomarkers for overall mortality in a high-risk cohort of
hematological malignancy patients (>80% of cases had received
mold-active antifungals at the time of sampling) undergoing
bronchoscopy for suspected pulmonary mold infection. Two
major findings are evident. First, elevated levels of IL-6 or IL-8
in blood or BAL fluid at the time of bronchoscopy was associated
with increased 30-day overall mortality. Second, increasing blood
levels of IL-8 within the 4 days following bronchoscopy were
highly predictive of overall 30- and 90-day mortality.
From prior studies, it is understood that cytokines are
centrally involved in protective immunity againstAspergillus spp.
and other molds (13, 21) and may therefore be used as an
early biomarker for risk stratification regarding IA associated
mortality (22). In the early stages of invasive aspergillosis
(IA), conidia are killed by local alveolar macrophage and IL-
8, also known as neutrophil chemotactic factor, is produced
by these macrophages as well as neighboring epithelial cells
as an important chemoattractant for neutrophils (11, 21). The
mechanism of IL-8 increase during IA has also been studied
in vitro where an up-regulation of gene transcription by
Aspergillus fumigatus proteases was shown to cause increased
release of IL-8 (as well as IL-6, which plays an important role
in T cell recruitment) by A549 pulmonary epithelial cells and
primary epithelial cells (16). Other studies have shown that
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FIGURE 1 | Boxplots of same-day serum and BAL cytokines in those who survived day 30 and those who died. On the boxplot shown here, outliers are identified by
different markers. “Out” values (small circle) and “far out” or as SPSS calls them “Extreme values” (marked with a star). SPSS uses a step of 1.5×IQR
(Interquartile range).
FIGURE 2 | Kinetics of median interleukin-8 plasma levels from 4 days before until 4 days after bronchoscopy stratified by overall mortality categories.
in vitro opsonization of Aspergillus fumigatus conidia with H-
ficolin, L-ficolin (17), and M-ficolin (which play essential roles
in pathogen recognition and complement activation through
the lectin pathway) potentiate IL-8 secretion of A549 lung
epithelial cells (12, 18, 19). In line, we have previously shown
that significantly better diagnostic performances were observed
for serum IL-8 and also serum IL-6 when compared to established
blood biomarkers (14).
It is worth noting that a number of other conditions/irritants
lead to increased levels of IL-6 and IL-8 in both blood and
lung environments. Studies have shown increased levels of
IL-6 and IL-8 in patients with tobacco smoke exposure and/or
chronic obstructive pulmonary disease (20), asthma (23), and
influenza infection (24), suggesting these are relatively non-
specific cytokines involved in responses to myriad insults
that may be visited upon the lungs. These other conditions,
including bacterial infections, may have boosted the prognostic
potential of these cytokines in our high-risk cohort where
IMI was suspected but only confirmed in a subset of cases,
as shown in results of our sub-analyses where cytokines were
also predictive of overall mortality in those with bacterial
and viral infection. As a limitation, prognostic potential of
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FIGURE 3 | Kinetics of median interleukin-6 plasma levels from 4 days before until 4 days after bronchoscopy stratified by overall mortality categories.
these cytokines may not be limited to patients with confirmed
IMI, but may extend to patients with suspected IMI who
subsequently are found to have other infections such as bacterial
pneumonia. This may, however, also be considered a strength
as it would allow for the use of these cytokines more broadly
for treatment stratification in hematological malignancy patients
with suspected pulmonary infection. While the clinical value
of single measurements of cytokines may be more limited (the
optimal cut-off for serum IL-8 yielded 82.4% sensitivity but only
61.8% specificity), serial measurements of these cytokines may be
more promising. Overall, studies and clinical trials with larger
sample sizes are needed to evaluate the prognostic potential of
serial measurements of these cytokines for various subgroups
of patients.
LIMITATIONS
Overall, fungal infections are rare in patients receiving anti-mold
prophylaxis, with a prevalence of 2–3% (25, 26), and therefore
multicenter studies are needed to confirm our findings in larger
cohorts. To avoid bias introduced by multiple comparisons
and confounding factors, we also had to rely on results from
smaller, nested matched case-control analysis for identification
of cytokines that were evaluated in the primary analyses of
this cohort study. Case-control pairs in this nested analysis
were matched for multiple covariates that may affect cytokine
levels (27).
Additionally, autopsies were performed only in a very small
subset of deceased patients and it is therefore likely that the
90- and 180-day mortality causes were not directly related to
the initial reason for bronchoscopy (e.g., suspected pulmonary
infection). It is still interesting that elevated levels of cytokines
had predictive value for mortality so far ahead, suggesting there
may be a component of specific immune dysregulation related
to these cytokines playing a role in mortality in patients with
underlying hematologic malignancies.
CONCLUSION
In conclusion, high blood and BAL IL-8 and IL-6 levels at the
time of bronchoscopy and, in particular, increasing cytokine
levels over time were predictive of mortality in a cohort of
patients with underlying hematologic malignancies presenting
with concern for pulmonary infection. These findings suggest it
could be possible to create a treatment algorithm incorporating
measurement of these cytokines at admission and throughout
initial treatment for the purpose of identifying patients who
warrant more aggressive treatment (e.g., combination treatment)
(28, 29) when IMI is suspected in at-risk individuals.
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